2023
Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatientsIn-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mahoney D, Maulion C, Bellumkonda L, Turner J, Collins S, Wilson F, Krumholz H, Testani J. In-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility. Circulation Heart Failure 2023, 16: e010206. PMID: 36896716, PMCID: PMC10186250, DOI: 10.1161/circheartfailure.122.010206.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureDiuretic responseDiuretic dosingOral diureticsHeart failureMulticenter cohortHospital observationLower readmission ratesNet fluid balanceDays postdischargeReadmission ratesHospital readmissionUrine outputReadmission riskFluid statusFluid balanceHospital measuresDose selectionCohortProvider decisionsWeight changeReadmissionDiureticsPatientsUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2022
Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original Research
2021
OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE
Dominguez Y, Pichert M, Alabi O, Huang J, Qurat-Ul-Ain J, Arham A, Brice A, Ahmed Z, Chaar C, Stacy M, Turner J, Smolderen K, Hurtado C. OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE. Journal Of The American College Of Cardiology 2021, 77: 1012. DOI: 10.1016/s0735-1097(21)02371-8.Peer-Reviewed Original Research
2020
Renal Disease in Older Adults
Turner J, Sharma D. Renal Disease in Older Adults. 2020, 265-276. DOI: 10.1007/978-3-319-47771-8_17.ChaptersCystatin C and Muscle Mass in Patients With Heart Failure
Ivey-Miranda JB, Inker LA, Griffin M, Rao V, Maulion C, Turner JM, Wilson FP, Tang WHW, Levey AS, Testani JM. Cystatin C and Muscle Mass in Patients With Heart Failure. Journal Of Cardiac Failure 2020, 27: 48-56. PMID: 32750487, PMCID: PMC8672303, DOI: 10.1016/j.cardfail.2020.07.013.Peer-Reviewed Original ResearchConceptsHeart failureCreatinine clearanceMuscle massCystatin CHigher muscle massAssociation of eGFRcysGlomerular filtration rateLow muscle massCystatin C levelsAccurate GFR estimationMultivariable analysisFiltration rateEGFRcysEGFRcrBody compositionGFR estimationPatientsCreatinineC levelsClearanceMortalityAssociationImpact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis
Anantha-Narayanan M, Sheikh AB, Nagpal S, Smolderen KG, Turner J, Schneider M, Llanos-Chea F, Mena-Hurtado C. Impact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis. American Journal Of Nephrology 2020, 51: 527-533. PMID: 32570255, DOI: 10.1159/000508575.Peer-Reviewed Original ResearchConceptsCKD/ESRDCritical limb ischemiaPAD interventionsMajor amputationEarly mortalitySystematic reviewCKD/ESRD patientsPeripheral arterial disease interventionsHigher major amputationOutcomes of patientsPeripheral arterial interventionsSuch comorbid conditionsESRD patientsLimb ischemiaArterial interventionsComorbid conditionsRandomized trialsKidney diseasePatient populationESRDObservational studyRisk populationsFunnel plotPatientsMeta-Analysis
2019
Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure
Griffin M, Rao VS, Fleming J, Raghavendra P, Turner J, Mahoney D, Wettersten N, Maisel A, Ivey-Miranda JB, Inker L, Tang WHW, Wilson FP, Testani JM. Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure. The American Journal Of Cardiology 2019, 124: 1707-1711. PMID: 31601358, PMCID: PMC6959849, DOI: 10.1016/j.amjcard.2019.08.034.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureHeart failureImproved survivalHigher loop diuretic dosesLoop diuretic dosesNet fluid lossPlasma volume reductionAggressive decongestionAggressive diuresisPostdischarge survivalDiuretic dosesPostdischarge outcomesSerum creatinineHospital treatmentHospital parametersBetter survivalCreatinineHemoconcentrationPatient carePatientsSurvivalLonger lengthVolume reductionTreatment
2018
Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done?
Kelley AT, Turner J, Doolittle B. Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done? The New Bioethics 2018, 24: 150-157. PMID: 29513084, DOI: 10.1080/20502877.2018.1438772.Peer-Reviewed Case Reports and Technical NotesConceptsAdvance care planningCare planningEnd-stage renal diseaseChronic kidney diseaseCourse of diseaseRenal diseaseKidney diseaseIntensive treatmentAdvance carePatient valuesCognitive declinePatientsSignificant mortalityClinical literatureDecision-making capacityDaily practiceDiseaseYears of supportPhysiciansConvincing evidenceMore trainingMorbidityHospitalClinicMortality
2017
Blood pressure targets for hemodialysis patients
Turner JM, Peixoto AJ. Blood pressure targets for hemodialysis patients. Kidney International 2017, 92: 816-823. PMID: 28938954, DOI: 10.1016/j.kint.2017.01.038.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDialysis unit blood pressureHemodialysis patientsBlood pressureBP targetsBlood pressure targetsLarge observational studiesBenefit-risk balanceBP reductionPressure targetsBP managementTreatment strategiesObservational studyCurrent evidenceDialysis providersGeneral populationClinical practicePatientsHypertensionNephrologistsPopulationTargetMortalityTrials
2016
Nutritional Supplements for the Treatment of Hypertension: A Practical Guide for Clinicians
Turner JM, Spatz ES. Nutritional Supplements for the Treatment of Hypertension: A Practical Guide for Clinicians. Current Cardiology Reports 2016, 18: 126. PMID: 27796863, DOI: 10.1007/s11886-016-0806-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsWe Avoid RAAS Inhibitors in PD Patients with Residual Renal Function
Turner JM. We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function. Seminars In Dialysis 2016, 29: 265-267. PMID: 27061273, DOI: 10.1111/sdi.12488.Commentaries, Editorials and LettersConceptsResidual renal functionPeritoneal dialysisRAAS inhibitorsRenal functionAngiotensin receptor blockersGlomerular filtration rateRAAS blockadeAldosterone systemReceptor blockersNephrotoxic agentsPD patientsPD populationFiltration rateModality failureUltrafiltration failureEnzyme inhibitorsPatientsPeritoneal membraneMorphologic changesInhibitorsMortalityCliniciansAnuriaAngiotensinFailure
2014
Do Any Patients with Acute Decompensated Heart Failure and Acute Cardio‐Renal Syndrome Benefit from Ultrafiltration?
Turner JM, Testani JM. Do Any Patients with Acute Decompensated Heart Failure and Acute Cardio‐Renal Syndrome Benefit from Ultrafiltration? Seminars In Dialysis 2014, 27: 231-233. PMID: 24620858, DOI: 10.1111/sdi.12221.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2013
Treatment of hyperkalemia
Turner J. Treatment of hyperkalemia. Expert Opinion On Orphan Drugs 2013, 1: 359-371. DOI: 10.1517/21678707.2013.794692.Peer-Reviewed Original ResearchTreatment strategiesTreatment of hyperkalemiaDegree of hyperkalemiaMyocardial cell membraneAdverse eventsCalcium administrationSerum potassiumCommon etiologyDigitalis toxicityClinical manifestationsPractice patternsPotassium imbalanceHyperkalemiaPotassium homeostasisDialysate solutionExcess potassiumDegree of riskRiskSafetyCellular uptakeReasonable cautionPatientsPathophysiologyMedical researchEtiology